endogenous retrovirus group MER34 member 1, envelopeGenealiases: HEMO · envMER34
Q-omics provides the consensus-scored ERVMER34-1 profile across patient tissues and cancer cell-line models. ERVMER34-1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in UVM. Among the 18 cancer types available for tumor–normal comparison, ERVMER34-1 is differentially expressed in 17, with the highest sampling consensus in KIRC. Additionally, ERVMER34-1 RNA expression shows 17,464 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight UVM, KIRC, and THYM as cancer lineages where ERVMER34-1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ERVMER34-1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ERVMER34-1 survival associations across molecular data types. ERVMER34-1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (2) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ERVMER34-1 RNA expression–survival associations across cancer types. High ERVMER34-1 expression shows unfavorable associations in UVM, KIRC, KIRP, COAD and HNSC, but favorable associations in OV. The UVM Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify UVM as the clearest survival context for ERVMER34-1 RNA expression.
This table summarizes ERVMER34-1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 17, while mass-spec protein shows differences in 1. The strongest signals are observed in KIRC for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for ERVMER34-1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ERVMER34-1 shows lower tumor expression in KIRC, KICH and KIRP and higher tumor expression in HNSC, BLCA and COAD. The KIRC box plot shows higher ERVMER34-1 RNA expression in normal versus tumor tissue (log2 FC = −3.179, t-test p < 0.001).
This table shows molecular features associated with ERVMER34-1 in patient tissues and cancer cell lines. In patient samples, ERVMER34-1 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, ERVMER34-1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BLOOD_Lymphoma, while CRISPR and shRNA rows add functional-dependency signals in LARGE_INTESTINE.
